title: [Renal toxicity by intraperitoneal administration of CDDP].
abstract: Renal toxicity following intraperitoneal (ip) CDDP therapy after laparotomy in twenty patients with ovarian cancer was examined. Four patients had renal toxicity. Patients who received CDDP at a dose of 150 mg (2/2) had a statistically higher incidence of toxicity than those who received less than 100 mg (2/18) (p less than 0.05). Patients who underwent ip therapy on the same day as laparotomy had a statistically higher incidence of the toxicity (4/15) than those underwent it on the fourth day after (0/5) (p less than 0.05). Renal toxicity was revealed in the mean urine volume of 1,100 ml on the day of therapy, but the toxicity did not appeared in those with a mean urine volume of 2,131 ml, whose volume was statistically different (p less than 0.01). These data suggest maintenance of renal blood flow during CDDP treatment plays an important role in preventing renal toxicity even following ip therapy. By investigating preoperative laboratory data, it is seen that patients with FDP values higher than 32 micrograms/ml have a higher risk of renal toxicity.
authors.affiliation: Department of Gynecology, Cancer Institute Hospital, Tokyo.
authors.forename: J T
authors.initials: JT
authors.lastname: Chen
authors.forename: T
authors.initials: T
authors.lastname: Yamashiro
authors.forename: Y
authors.initials: Y
authors.lastname: Shimizu
authors.forename: T C
authors.initials: TC
authors.lastname: Kuo
authors.forename: K
authors.initials: K
authors.lastname: Nakayama
authors.forename: H
authors.initials: H
authors.lastname: Teshima
authors.forename: Y
authors.initials: Y
authors.lastname: Hirai
authors.forename: T
authors.initials: T
authors.lastname: Hamada
authors.forename: I
authors.initials: I
authors.lastname: Fujimoto
authors.forename: K
authors.initials: K
authors.lastname: Yamauchi
mesh_terms: D000328:Adult; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D003131:Combined Modality Therapy; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D006801:Humans; D007274:Injections, Intraperitoneal; D007668:Kidney / Q000187:drug effects*; D007674:Kidney Diseases / Q000139:chemically induced* / Q000517:prevention & control; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000601:surgery; D012079:Renal Circulation; D012307:Risk Factors
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; D002945:Cisplatin